Phase II Trial of AZD6738 Alone and in Combination With Olaparib
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Locally Advanced Pancreatic Cancer
- Clear Cell Renal Cell Carcinoma
- Locally Advanced Malignant Solid Neoplasm
- Metastatic Malignant Solid Neoplasm
- Metastatic Pancreatic Cancer
- Metastatic Renal Cell Carcinoma
- Metastatic Urothelial Carcinoma
- Stage III Pancreatic Cancer
- Stage III Renal Cell Cancer
- Stage IV Pancreatic Cancer
- Stage IV Renal Cell Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
PRIMARY OBJECTIVES: I. To assess objective response rate (ORR) of ATR kinase inhibitor AZD6738 (AZD6738) monotherapy and AZD6738 + olaparib by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. SECONDARY OBJECTIVES: I. To determine the median duration of response (DOR) in each study...
PRIMARY OBJECTIVES: I. To assess objective response rate (ORR) of ATR kinase inhibitor AZD6738 (AZD6738) monotherapy and AZD6738 + olaparib by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. SECONDARY OBJECTIVES: I. To determine the median duration of response (DOR) in each study arm. II. To determine the median progression-free survival and progression-free survival rate at 6 and 12 months in each study arm. III. To further characterize the safety and tolerability profile of AZD6738 alone and in combination with olaparib.
Tracking Information
- NCT #
- NCT03682289
- Collaborators
- AstraZeneca
- Investigators
- Principal Investigator: Rahul Aggarwal University of California, San Francisco
Get Well Soon